ArticleCell reports. Medicine2022

Phase 1 multicenter, dose-expansion study of ARX788 as monotherapy in HER2-positive advanced gastric and gastroesophageal junction adenocarcinoma.

Yang Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.